SBIR/STTR Research Award

A Multiplexed Immunoassay System for Clinical Oncology

Award identifier b2e556b908316c3248fb4e373b46b212914bc6635461d4a3058086d620a8f126Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$247,126

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Decision Biomarkers, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Protein biomarker candidates for a range of malignancies are being discovered at an escalating pace presenting the enormous challenge of identifying those with clinical utility. NIH/NCI has established serum banks with linked clinical outcomes that are vital resources for screening and validating new cancer biomarkers. However, the increasing demand for the limited serum samples contained in these banks has created a bottle-neck in biomarker validation. In this project, we will address the need for new technology that will make more efficient use of valuable serum banks. We propose to develop and test a platform with a 20-fold or greater increase in the number of biomarkers that can be assayed with a 100ul unit volume of serum. In Phase I, we will develop and evaluate a model multiplexed immunoassay for cancer related biomarkers, and in the process adapt and validate novel, proprietary substrate and imaging technologies for this application. Initially, we will qualify a candidate substrate with novel composition as a support for immunoassays by comparing its performance to commercial protein-array substrates. Next, we will develop an array format Cancer Antigen (CA) 125 immunoassay with performance comparable to the CA125 ELISA. The CA125 assay will then act as a platform with which to evaluate alternative fluorescence labels for their compatibility with the multiplexing technology. The label with the highest performance will be used for subsequent assay development. Finally, a multiplexed immunoassay for three cancer-relevant markers will be developed, optimized and evaluated using the prototype imager and a panel of patient and control serum samples. In Phase II, a full-scale development program is planned to integrate assay automation and processing instrumentation, and for evaluating the multiplexed immunoassay system as an efficient technology for screening serum banks to validate biomarkers for cancer diagnosis and management.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.